Barriers to Care in Migraine in Germany

Study identification

• EU PAS number:
  EUPAS44516
• Study ID:
  50348
• Official title and acronym:
  Barriers to Care in Migraine in Germany
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  The study is a prospective anonymous cross-sectional study using a web-based survey. Participants with headache are eligible to enter the survey. First step will be a screening for potential migraine using the ID-MigraineTM questionnaire. Participants will be subsequently stratified to three different questionnaires based on their potential migraine diagnosis not made by a physician (survey1), migraine with a medical diagnosis (without preventive medication experience) (survey 2), migraine with medical diagnosis (with preventive medication experience) (survey 3). The study will address the impact of potential predictors of barriers to migraine
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Planned:17/06/2021

Actual:17/06/2022

Study start date

Planned:02/12/2021

Actual:02/12/2022

Date of final study report

Planned:01/12/2022

Actual:03/01/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Teva GmbH

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable